NasdaqGS:ALKSBiotechs
Should Alkermes’ (ALKS) New Phase 3 Narcolepsy Program Reshape Its Sleep-Disorder Investment Narrative?
In early April 2026, Alkermes plc announced that it had initiated the Brilliance phase 3 program to evaluate its oral orexin 2 receptor agonist alixorexton in adults with narcolepsy type 1 and type 2 across three 12-week, randomized, double-blind, placebo-controlled studies.
The launch of these global Brilliance Studies marks a significant step in advancing orexin-targeted therapies, potentially broadening Alkermes’ footprint in sleep-wake disorders if outcomes are favorable.
With phase 3...